Andere talen Tango Therapeutics, Inc.

Aandelen

TNGX

US87583X1090

Geschatte realtime Cboe BZX Andere beurzen 17:55:48 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,555 ^USD	-0,46%		+1,75%	-23,54%

04/04	Britse miljardair Joe Lewis krijgt $5 miljoen boete van Amerikaanse rechter voor handel met voorkennis	RE
04/04	Miljardair Joe Lewis wordt in VS veroordeeld voor handel met voorkennis	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

British billionaire Joe Lewis fined $5 million by US judge for insider trading	04/04
Multibillionaire Joe Lewis to face US sentencing for insider trading	04/04
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	18/03
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	18/03
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index	18/03
Tango Therapeutics to Participate in Upcoming Investor Conferences	06/03
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	05/03
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	31/01
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	24/01
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/01
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04/01
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04/01
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348	03/01
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	03/01
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers	03/01
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	13/11
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tango Therapeutics, Inc.

Aandelen

TNGX

US87583X1090

Andere talen

Filters